Summary & Overview
HCPCS J0801: Corticotropin (Acthar Gel) Injection, up to 40 Units
HCPCS Level II code J0801 denotes an injection of corticotropin (Acthar Gel), billed per unit (up to 40 units). Nationally, this code matters because corticotropin is a high-cost, specialty biologic used for select inflammatory, autoimmune, and rare disease indications; accurate coding affects coverage determinations, prior authorization workflows, and cost reporting. Key payers for national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of clinical context, typical sites of service (outpatient clinic, physician office, ambulatory infusion center), and the implications for billing teams and revenue cycle operations. The publication outlines common modifiers in use and typical payer interactions, and it provides benchmarks and policy considerations where available. It also highlights areas where payers may require documentation or prior authorization and summarizes coding nuances relevant to billing accuracy and claims adjudication.
Data not available in the input are noted where applicable. This piece is intended as a national reference to support coding clarity and payer engagement on claims involving corticotropin administration under J0801.
Billing Code Overview
HCPCS Level II code J0801 describes an injection of corticotropin (Acthar Gel), up to 40 units. This billing code represents the administration of a therapeutic biologic agent used for inflammatory and autoimmune conditions where corticotropin is indicated.
Service type: Therapeutic injection
Typical site of service: Outpatient clinic, physician office, or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with severe, refractory nephrotic syndrome presents to an outpatient specialty infusion clinic for administration of corticotropin (repository corticotropin injection, Acthar Gel). The patient has previously failed or had contraindications to first-line systemic corticosteroids and immunosuppressive regimens. The ordering physician is typically a nephrologist or rheumatologist who documents the indication, dosing (up to 40 units per dose as provided by billing code J0801), and schedule. The clinic verifies insurance authorization prior to the visit. On arrival, nursing performs a focused assessment including vital signs, allergies, and recent laboratory results (electrolytes, glucose, renal function). The medication is prepared under sterile technique and administered by an RN via subcutaneous or intramuscular injection per product instructions. The administration encounter includes medication reconciliation, observation for immediate adverse effects, and documentation of lot number, dose, route, site, and the J0801 billing code with applicable modifier(s). Follow-up includes monitoring response (proteinuria, edema, serum albumin) and adverse effects; subsequent doses are scheduled based on clinical response and payer authorization. Typical sites of service include outpatient infusion centers, physician offices, and ambulatory clinics. Patient education on potential side effects (fluid retention, increased glucose, hypertension) is provided at discharge.
Coding Specifications
| Modifier | Description | When to Use |
|---|